See the DrugPatentWatch profile for Bicalutamide
Is bicalutamide patented, and when would a patent typically expire?
Bicalutamide (sold as Casodex) is an older cancer medicine, so patents and exclusivity rights have generally moved into later life phases, including multiple patent filings, renewals, and—depending on country—eventual expiry. Whether a specific bicalutamide patent is still active depends on the exact patent family, the jurisdiction (US, EU, UK, etc.), and the specific claim (drug substance vs. formulation vs. method of use).
If you tell me the country (or whether you mean US/EU/UK) and any patent number you’ve seen, I can help interpret what that specific “bicalutamide patent” covers and how long it would last.
Which kinds of patents cover bicalutamide (and why that matters)?
For oncology drugs like bicalutamide, patent coverage commonly spans:
- Drug substance (the active ingredient and its chemical claims)
- Formulations (how the drug is made or presented, such as tablets)
- Methods of use (specific dosing regimens or clinical uses)
- Process patents (how the active ingredient is manufactured)
Even if the original substance patent has expired, later filings can affect when certain generic or “next” versions can enter in some markets.
Are generics available, and can they launch without violating patent rights?
When relevant patents or exclusivity periods expire in a given country, generic manufacturers can typically enter with bioequivalent products. If any patents remain (for example, on a specific formulation or dosing method), generics can be delayed or launched under regulatory pathways that address patent disputes.
What’s the difference between patent expiry and market exclusivity?
Patent expiry is about when specific legal claims end. Market exclusivity can include additional protections that delay generic competition even after some patents expire, depending on jurisdiction and the drug’s regulatory history.
How can you find the exact bicalutamide patent you mean?
“Bicalutamide paten” could refer to multiple patents. To pinpoint the right one, you can use:
- Patent number(s) from a label or dispute document
- The applicant/assignee name (often differs across patent families)
- The jurisdiction (US vs EP vs UK)
- The drug product name tied to the patent (Casodex, bicalutamide tablets, etc.)
Share any of the above (even a partial patent number), and I’ll help you map it to scope and likely timing.
Quick check: which country and patent identifier do you have?
Reply with either:
1) the country (US/EU/UK/other), and
2) any patent number or link you’re looking at,
and I’ll give a direct answer about what that particular bicalutamide patent covers and when it’s expected to expire.